Late Treatment with a Protective Antigen–Directed Monoclonal Antibody Improves Hemodynamic Function and Survival in a Lethal Toxin–Infused Rat Model of Anthrax Sepsis | Zendy

Xizhong Cui | Zendy; Yan Li | Zendy; Mahtab Moayeri | Zendy; Gil H. Choi | Zendy; G. Mani Subramanian | Zendy; Xuemei Li | Zendy; Michael Haley | Zendy; Yvonne Fitz | Zendy; Jing Feng | Zendy; Steven M. Banks | Zendy; Stephen H. Leppla | Zendy; Peter Q. Eichacker | Zendy

Open Access

Late Treatment with a Protective Antigen–Directed Monoclonal Antibody Improves Hemodynamic Function and Survival in a Lethal Toxin–Infused Rat Model of Anthrax Sepsis

Author(s) -

Xizhong Cui,

Yan Li,

Mahtab Moayeri,

Gil H. Choi,

G. Mani Subramanian,

Xuemei Li,

Michael Haley,

Yvonne Fitz,

Jing Feng,

Steven M. Banks,

Stephen H. Leppla,

Peter Q. Eichacker

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/427189

Subject(s) - bacillus anthracis , monoclonal antibody , toxin , anthrax toxin , antigen , microbiology and biotechnology , sepsis , immunology , septic shock , antibody , medicine , shock (circulatory) , biology , pharmacology , bacteria , recombinant dna , biochemistry , gene , fusion protein , genetics

In animal models, treatment with 5H3, a fully human protective antigen-directed monoclonal antibody (PA-MAb), improved survival when administered close to the time of Bacillus anthracis lethal toxin (LeTx) bolus or live bacterial challenge. However, treatment with PA-MAb would be most valuable clinically if it were beneficial even when administered after the onset of shock and lethality due to LeTx.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research